# Attune Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/attune-pharmaceuticals

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.attunepharma.com
- Total disclosed funding: $23M
- Latest round: Series B (Jan 23, 2019)
- Investors on record: 6

## About

Founded in 2015 and based in New York, US, Attune Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel, orally-administered, and small-molecule therapeutics for the treatment of rare diseases. The company's pipeline includes Hereditary Angioedema (HAE), a rare and potentially life-threatening genetic condition resulting from the over-production of bradykinin caused by a genetic deficiency in C1 inhibitor; Paroxysmal Nocturnal Hemoglobinuria (PNH), an ultra-rare and life-threatening disease resulting from the chronic hemolysis of a patient’s red blood cells (RBCs); and Complement Pathway Inhibition, a part of the innate immune system and is comprised of a group of serum proteins that are activated through sequential protease based steps.

## Funding rounds

- Series B, Jan 23, 2019, $23M — Venrock, Tang Capital Management, RTW Investments, RA Capital Management, Boxer Capital, LifeSci Partners

## Investors

- Venrock (https://capitalatlas.ai/funds/venrock) — Series B
- Tang Capital Management — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Boxer Capital (https://capitalatlas.ai/funds/boxer-capital) — Series B
- LifeSci Partners (https://capitalatlas.ai/funds/lifesci-partners) — Series B